Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Administration of the Probiotic Escherichia coli Strain A0 34/86 Resulted in a Stable Colonization of the Human Intestine During the First Year of Life

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F20%3A00114097" target="_blank" >RIV/00216224:14110/20:00114097 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/00216305:26230/19:PU135643

  • Výsledek na webu

    <a href="https://link.springer.com/article/10.1007%2Fs12602-019-09548-3" target="_blank" >https://link.springer.com/article/10.1007%2Fs12602-019-09548-3</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1007/s12602-019-09548-3" target="_blank" >10.1007/s12602-019-09548-3</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Administration of the Probiotic Escherichia coli Strain A0 34/86 Resulted in a Stable Colonization of the Human Intestine During the First Year of Life

  • Popis výsledku v původním jazyce

    Colinfant New Born (CNB) is an orally administered probiotic preparation containing theEscherichia colistrain A0 34/86, which is specially marketed for use in newborns and infants. Although the impact of different probiotics on the composition of the human gut microbiota has been previously described, the effects ofE. coliprobiotic consumption during infancy on the development of intestinal microbiota are not known. The effect of oral administration of CNB on theEnterobacteriaceaepopulation was mapped using 16S rRNA gene sequencing in DNA samples isolated from the stools of one infant collected at 177 different time points during the first year of life.E. colistrains turnover was analyzed based on the detection of 26 genetic determinants, phylogroups, and pulsed-field gel electrophoresis (PFGE) analysis. Administration of CNB during the second and third month of life introduced theEscherichiagenus to the infant's intestinal tract, andEscherichiabecame dominant among theEnterobacteriaceaefamily (p &lt; 0.01). Genetic determinants, typical for probioticE. coliA0 34/86 strain, were detected on the first day after application of CNB and persisted all year. In addition, nine transientE. colistrains were identified; these strains harbored different genetic determinants and showed different PFGE profiles. Transient strains were detected from 2 to 24 days in the stool samples. The firstEscherichiacolonizer originated from the application of the CNB probiotic preparation. ProbioticE. coliA0 34/86 successfully colonized the intestinal tract of an infant and became resident during the first year of life.

  • Název v anglickém jazyce

    Administration of the Probiotic Escherichia coli Strain A0 34/86 Resulted in a Stable Colonization of the Human Intestine During the First Year of Life

  • Popis výsledku anglicky

    Colinfant New Born (CNB) is an orally administered probiotic preparation containing theEscherichia colistrain A0 34/86, which is specially marketed for use in newborns and infants. Although the impact of different probiotics on the composition of the human gut microbiota has been previously described, the effects ofE. coliprobiotic consumption during infancy on the development of intestinal microbiota are not known. The effect of oral administration of CNB on theEnterobacteriaceaepopulation was mapped using 16S rRNA gene sequencing in DNA samples isolated from the stools of one infant collected at 177 different time points during the first year of life.E. colistrains turnover was analyzed based on the detection of 26 genetic determinants, phylogroups, and pulsed-field gel electrophoresis (PFGE) analysis. Administration of CNB during the second and third month of life introduced theEscherichiagenus to the infant's intestinal tract, andEscherichiabecame dominant among theEnterobacteriaceaefamily (p &lt; 0.01). Genetic determinants, typical for probioticE. coliA0 34/86 strain, were detected on the first day after application of CNB and persisted all year. In addition, nine transientE. colistrains were identified; these strains harbored different genetic determinants and showed different PFGE profiles. Transient strains were detected from 2 to 24 days in the stool samples. The firstEscherichiacolonizer originated from the application of the CNB probiotic preparation. ProbioticE. coliA0 34/86 successfully colonized the intestinal tract of an infant and became resident during the first year of life.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    10606 - Microbiology

Návaznosti výsledku

  • Projekt

    Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

  • Návaznosti

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2020

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Probiotics and Antimicrobial Proteins

  • ISSN

    1867-1306

  • e-ISSN

    1867-1314

  • Svazek periodika

    12

  • Číslo periodika v rámci svazku

    2

  • Stát vydavatele periodika

    US - Spojené státy americké

  • Počet stran výsledku

    8

  • Strana od-do

    343-350

  • Kód UT WoS článku

    000541342000003

  • EID výsledku v databázi Scopus

    2-s2.0-85065563862